|Awarded On||August 19, 2020|
|Title||A Novel Organoid Platform to Modulate Human Neural Networks Integrated with Glioblastoma Stem Cells|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The Methodist Hospital Research Institute|
|Principal Investigator/Program Director||Robert Krencik|
|Cancer Sites||Brain and Other Nervous System|
*Pending contract negotiation
Our goal is to establish a new and well-defined experimental human-derived cellular tool that can serve as a drug testing platform for brain cancers, including glioblastoma. This tool will consist of patient-derived glioblastoma stem cells systematically incorporated within human neural cells that are rapidly derived from pluripotent stem cells. We will also incorporate a method to pace neural activity within the platform which will enable modeling of human brain activity. The significance of this project is that it is expected to provide a new drug testing platform that is a better recapitulation of the brain environment as compared to existing technologies and, thus, it will accelerate the...